NOX-H94: Clinical Trials

4 trials of NOX-H94, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Phase 22Completed 2

Follow NOX-H94: new trials by email Literature Review of NOX-H94 trials Research Report on NOX-H94

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients
Lexaptepid pegol (NOX-H94), Placebo - Anemia, End Stage Renal Disease
Phase 1 / Phase 2CompletedTME Pharma AG332014-05-012015-11-24
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
NOX-H94, Placebo solution - Anemia of Chronic Disease
Phase 2CompletedTME Pharma AG122012-09-012014-06-26
Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model
NOX-H94, Placebo solution - Anemia of Chronic Disease
Phase 1CompletedTME Pharma AG242012-01-012014-11-10
First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94
NOX-H94, Glucose 5% - Anemia, Chronic Diseases
Phase 1CompletedTME Pharma AG642011-07-012016-01-25

Conditions studied

Anemia (3)  ·  Chronic Disease (1)  ·  Inflammation (1)  ·  Kidney Failure, Chronic (1)  ·  Lymphoma (1)  ·  Multiple Myeloma (1)  ·  Neoplasms (1)

Sponsors

TME Pharma AG (4)

Countries

United Kingdom (2)  ·  Austria (1)  ·  Bulgaria (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Romania (1)

Top investigators

Kai Riecke, MD (3)  ·  Peter Pickkers, MD, PhD (1)  ·  Riecke Kai, MD (1)

Results publications

PMID 30957581, PMID 25163699